C.T. Fitzpatrick’s AstraZeneca AZN Stock Holding History

C.T. Fitzpatrick’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-3,125	Closed	-$212K	–	57
2015 Q4	$212K	Buy	+3,125	New	+$205K	﹤0.01%	60

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Cambiar Investors Denver, Colorado $2.3B AUM 24.77% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

SCCM

Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

C.T. Fitzpatrick's AZN Position: Q1 2016 in Review

C.T. Fitzpatrick sold out of AstraZeneca (AZN) in Q1 2016, closing a stake of 3,125 shares — an estimated $212K sold.

C.T. Fitzpatrick first reported a position in AZN in Q4 2015 and held it in 1 quarter. The position peaked at $212K in Q4 2015. 390 funds tracked by Wall St. Rank hold AZN as of Q1 2016.

C.T. Fitzpatrick reported no remaining AstraZeneca position as of Q1 2016 after selling out during the quarter.
C.T. Fitzpatrick sold 3,125 AstraZeneca shares in Q1 2016, an estimated $212K.
C.T. Fitzpatrick first reported a position in AstraZeneca in Q4 2015 and held it in 1 quarter.
C.T. Fitzpatrick's AstraZeneca position peaked at $212K in Q4 2015.
390 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2016.

Based on Vulcan Value Partners's 13F filing for Q1 2016, filed 18 May 2016.